Pulmonology

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

Phase 3 TETON-1 data show inhaled treprostinil reduced FVC decline by 130 mL and cut clinical worsening risk 33% in IPF patients over 52 weeks, according to Steven Nathan, MD.

5 interviews in 5 minutes. Check out this HCPLive Five at ATS 2026 on late breaking data in sleep apnea, lung function recovery, PAH, lung disease, and COPD.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

At ATS 2026, Sarath Raju, MD, discussed retrospective data linking SGLT2 inhibitor use to reduced 30-day readmissions in patients hospitalized for AE-COPD and diabetes.

At ATS 2026, Krunal Patel, MD, discussed early real-world data suggesting sotatercept may improve hemodynamics, RV remodeling, and functional outcomes in group 3 CLD-PH.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.

A quantitative CT-based approach may help predict pneumothorax risk after bronchoscopic lung volume reduction, according to findings presented at ATS 2026.

ATS 2026 data presented by Jamey Moore, DO, suggest greater upfront corticosteroid dosing may shorten hospitalization in acute exacerbations of autoimmune-related ILD.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.